Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
|Videos|November 15, 2021
With Oral Agents Common, Oncology Pharmacists Are Essential in Treatment of Multiple Myeloma
With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members.
Advertisement
With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members, according to Terri L. Parker, MD, assistant medical director of Smilow Cancer Hospital Care Center at Yale New Haven Health.
In an interview, Parker discussed key considerations for treatment selection, safety data on the drug selinexor, the importance of facilitating collaboration between experts, and upcoming clinical trials and research that she is keeping an eye on.
Advertisement
Related to this article
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Payer requirements, prescriber habits, and operational realities ultimately determine which ICI patients receive.
Accelerated approval for patients who progressed on platinum and immunotherapy brings a new mechanism—and a familiar toxicity profile.
If approved, the combination would be the first chemotherapy-free, Bruton tyrosine kinase inhibitor–based regimen for adults with newly diagnosed mantle cell lymphoma (MCL).
Manufacturing delays, financial barriers, and complex care coordination can limit access to gene therapy, emphasizing the need for patient-centered programs and long-term follow-up.
Experts highlighted how Diamond-Blackfan anemia illustrates the scientific, financial, and manufacturing challenges that can prevent promising gene therapies for ultra-rare diseases from reaching patients.
Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Frontline Immunotherapy Options in NSCLC: Are Checkpoint Inhibitors Interchangeable?
2
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL
3
What Drives First-Line Immunotherapy Selection in NSCLC? Data, Payers, and Habit
4
AHA 2026: Insights on Oral PCSK9, Survodutide, and HF Care Come to Chicago
5